To the full analysis
Buyback calculator for Laboratorios Farmaceuticos Rovi
Laboratorios Farmaceuticos Rovi stock: key metrics
ROVI.MCLaboratorios Farmaceuticos Rovi had an operating margin of 23.3% and a return on invested capital (ROIC) of 19.4% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 66.9% | 4.4% | 6.4% |
| 2007 | 67.3% | 18.3% | 14.9% |
| 2008 | 68.4% | 22.2% | 18.5% |
| 2009 | 56.3% | 12.1% | 20.1% |
| 2010 | 60.4% | 16.4% | 15.5% |
| 2011 | 62.4% | 10.3% | 9.8% |
| 2012 | 62.6% | 10.7% | 9.7% |
| 2013 | 61.0% | 11.7% | 10.6% |
| 2014 | 60.3% | 11.6% | 10.1% |
| 2015 | 60.5% | 8.9% | 8.1% |
| 2016 | 57.8% | 10.7% | 9.8% |
| 2017 | 60.8% | 6.9% | 6.3% |
| 2018 | 57.6% | 5.8% | 5.9% |
| 2019 | 56.3% | 11.2% | 10.3% |
| 2020 | 57.5% | 17.8% | 14.5% |
| 2021 | 59.3% | 28.0% | 23.6% |
| 2022 | 63.5% | 31.3% | 24.4% |
| 2023 | 58.3% | 26.6% | 20.5% |
| 2024 | 62.6% | 23.5% | 17.9% |
| 2025 | 60.7% | 23.3% | 18.9% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 19.6% | 14.1% | 6.7% |
| 2007 | 28.8% | 34.0% | 13.3% |
| 2008 | 48.6% | 39.2% | 19.5% |
| 2009 | 32.4% | 19.7% | 13.9% |
| 2010 | 23.6% | 31.0% | 11.5% |
| 2011 | 15.9% | 19.3% | 7.9% |
| 2012 | 15.4% | 16.4% | 8.8% |
| 2013 | 15.9% | 15.9% | 9.8% |
| 2014 | 15.2% | 16.1% | 9.2% |
| 2015 | 12.0% | 12.0% | 7.5% |
| 2016 | 14.2% | 15.0% | 9.1% |
| 2017 | 9.0% | 10.3% | 5.8% |
| 2018 | 6.2% | 8.3% | 4.4% |
| 2019 | 12.2% | 14.2% | 7.7% |
| 2020 | 16.3% | 17.1% | 10.6% |
| 2021 | 32.5% | 36.3% | 20.9% |
| 2022 | 38.4% | 43.3% | 22.7% |
| 2023 | 31.6% | 32.3% | 21.3% |
| 2024 | 23.9% | 22.1% | 16.5% |
| 2025 | 21.1% | 19.4% | 14.7% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Apr 2025)
- Valuation signal Undervalued since 12 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.